Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alnylam Pharmaceuticals has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate and characterize the molecular mechanisms underlying intracellular transport of small interfering RNA, the molecules that mediate RNA interference.
Subscribe to our email newsletter
Alnylam said that its scientists will work closely with the laboratory of Marino Zerial, whose team is internationally recognized as being at the forefront of the intracellular trafficking field and have the needed expertise and capabilities to investigate cellular uptake pathways in a robust and high-throughput manner. Alnylam will have an option on any intellectual property that results from this agreement.
Victor Kotelianski, vice president for research at Alnylam, said: “Alnylam has a long-standing commitment to scientific excellence in the field of RNA interference (RNAi) therapeutics and our new collaboration with Mr Zerial and his team is representative of the collaborations we have and will continue to form as we seek to increase our understanding of the underlying mechanism of cellular delivery of RNAi therapeutics.”